BREEZE HLDGS ACQ.DL-,0001

YD Biopharma is a Clinical-Stage Biopharmaceutical Company Focusing on Cancer Prevention Diagnostics and Seeking to Transform the Treatment of a Wide Spectrum of Diseases» Mehr auf globenewswire.com

IRVING, Texas, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Breeze Holdings Acquisition Corp. (OTCQX: BRZH) (“Breeze” or the “Company”), has been informed its application to trade on the OTCQX Best Market has been approved. As a result, the Company's common stock and warrants under the tickers “BRZH” and “BRZHW,” respectively, have begun trading on the OTCQX, effective today, August 21, 2024.» Mehr auf globenewswire.com

IRVING, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Breeze Holdings Acquisition Corp. (Nasdaq: BREZ) (the “Company”), today announced that on March 15, 2024, the Company received a notification from Nasdaq indicating that the Nasdaq Hearings Panel (the “Panel”) had granted the Company's request for continued listing on the exchange. In accordance with the Panel's determination, the Company must complete its initial business combination by May 28, 2024, and must demonstrate compliance with Nasdaq's initial listing requirements under Nasdaq Listing Rule 5405. The Panel's determination related to a previously disclosed notice the Company received from Nasdaq on November 27, 2023, relating to the Company's non-compliance with Nasdaq IM-5101-2, which requires that a special purpose acquisition company complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement.» Mehr auf globenewswire.com